BUSINESS

Chinese Skincare Company Refutes ‘False Advertising’ Claims

Published: Jun. 6, 2025 8:09 p.m. GMT+8

00:00

00:00/00:00

Listen to this article 1x

The public feud has dragged down both skincare specialists’ share prices: Giant Biogene’s stock fell 8.7% in Hong Kong on Thursday, while Bloomage Biotech’s dropped nearly 2% in Shanghai. Photo: AI generated

Chinese collagen skincare developer Giant Biogene Holding Co. Ltd. has refuted claims that one of its best-selling products is falsely labeled, the latest development in a spat with a domestic rival.

In a social media post Wednesday, Hong Kong-listed Giant Biogene defended the Comfy-branded skincare essence as having a concentration of recombinant collagen exceeding the 0.1% weight per weight amount required under Chinese cosmetics labeling rules, citing test results it commissioned from several third-party laboratories.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.

Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.

Share this article

Open WeChat and scan the QR code

DIGEST HUB

Digest Hub

Back

Explore the story in 30 seconds

Giant Biogene refuted claims that its Comfy product is falsely labeled, citing third-party test results.
The accusation originated from a beauty blogger linked to Giant Biogene's rival, Bloomage Biotech.
The dispute has impacted both companies' stock prices and highlights a rivalry in the skincare market.

AI generated, for reference only

Who’s Who

Giant Biogene Holding Co. Ltd.: Giant Biogene Holding Co. Ltd. is a Chinese collagen skincare developer. It has been involved in a public dispute with rival Bloomage Biotechnology Corp. Ltd. regarding product labeling and efficacy claims. Giant Biogene specializes in collagen-based products, with revenue significantly increasing in 2024, largely from skincare.

Bloomage Biotechnology Corp. Ltd.: Bloomage Biotechnology Corp. Ltd. is a Chinese company primarily selling hyaluronic acid-based skincare products. It is engaged in a public feud with rival Giant Biogene, including claims of false advertising and online smear campaigns. Bloomage Biotech has seen a decline in revenue from its skincare products and aims to diversify into collagen-based products.

AI generated, for reference only

What Happened When

2022：: Nearly 70% of Giant Biogene's revenue came from skincare products. Bloomage Biotech Chairwoman Zhao Yan said the company would diversify into collagen-based skincare products.

2023：: Bloomage Biotech's downward revenue trend began; 70% of its revenue that year came from skincare products.

2024：: Less than half of Bloomage Biotech's revenue came from skincare products, compared with 70% in 2023.

2024：: Giant Biogene booked 5.5 billion yuan in revenue, up 57.2% from 2023, with nearly 80% of its revenue from skincare products.

In the first quarter of 2025：: Bloomage Biotech reported a 20.8% drop in revenue from the previous year, continuing a downward trend that began in 2023.

Since mid-May 2025：: Bloomage Biotech began publishing articles accusing Giant Biogene of belittling the efficacy of hyaluronic acid.

May 24, 2025：: Chinese beauty blogger Hao Yu posted a video online accusing Giant Biogene of misleading consumers with false advertising about the amount of recombinant collagen in its Comfy product.

June 1, 2025：: Bloomage Biotech published a statement revealing its stake in a fund linked to Hao Yu and claimed that Liuyue Medical is part of the Bloomage Biotech ecosystem.

June 1, 2025：: Giant Biogene shared a letter of apology from the testing company Hao hired, in which the testing company revoked the test report Hao used.

Wednesday, June 4, 2025：: Giant Biogene publicly refuted claims regarding false labeling of its Comfy-branded skincare essence on social media, citing third-party test results.

Thursday, June 5, 2025：: Giant Biogene's stock fell 8.7% in Hong Kong and Bloomage Biotech's dropped almost 2% in Shanghai due to the public feud.

AI generated, for reference only